Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.
What is Neoleukin Therapeutics's quote symbol?
What is the 52 week high and low for Neoleukin Therapeutics (NASDAQ: NLTX)?
How much is Neoleukin Therapeutics stock worth today?
How much is Neoleukin Therapeutics's stock price per share?
What is Neoleukin Therapeutics's Market Cap?